Drug Trial Radar · NCT06409130
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
270
Actual
Start
May 20, 2024
Primary completion
Nov 21, 2025
Study completion Jan 12, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- May 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Conditions
- Alcohol-related Liver Disease
Interventions
NNC0194-0499Drug
Administered subcutaneously.
SemaglutideDrug
Administered subcutaneously.
NNC0194-0499 placeboDrug
Administered subcutaneously.
Semaglutide placebo (Group A)Drug
Administered subcutaneously.
Cagrilintide + semaglutideDrug
Administered subcutaneously.
CagrilintideDrug
Administered subcutaneously.
Cagrilintide placeboDrug
Administered subcutaneously.
Semaglutide placebo (Group B)Drug
Administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Enhanced Liver Fibrosis (ELF)Time frame: From week 0 to week 28
Locations
102 sites in 14 countries. Site status is shown where the registry gives one.
The Institute for Liver Health
Chandler, Arizona
Arizona Liver Center
Tucson, Arizona
Del Sol Research Management, LLC
Tucson, Arizona
OM Research LLC
Lancaster, California
California Liver Research Institute
Pasadena, California
Covenant Metabolic Specialists LLC
Fort Myers, Florida
Miguel Rebollar PA
Hialeah, Florida
UF Hlth Jacksonville
Jacksonville, Florida
Univ of Miami/Schiff Ctr
Miami, Florida
Covenant Metabolic Specialists LLC
University Park, Florida
Rush University Med. Cntr
Chicago, Illinois
Kansas Medical Clinic, PA
Topeka, Kansas
Louisiana Research Center, LLC
Shreveport, Louisiana
Boston Medical Center_Cary
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
Jubilee Clinical Research, Inc.
Las Vegas, Nevada
DSI Research,LLC
Springboro, Ohio
Univ of Pennsylvania Hospital
Philadelphia, Pennsylvania
UPMC_Center for Liver Care
Pittsburgh, Pennsylvania
Digestive Health Research, TN
Hermitage, Tennessee
Texas Clinical Research Institute
Arlington, Texas
The Liver Institute
Dallas, Texas
South Texas Research Institute
Edinburg, Texas
Baylor St. Luke's Medical Center
Houston, Texas
Houston Research Institute
Houston, Texas
Amer. Rrsch Corp-TX Liver Inst
San Antonio, Texas
Pinnacle Clinical Research
San Antonio, Texas
Liver Specialists of Texas
Sugar Land, Texas
Velocity Clinical Res, Waco
Waco, Texas
Momentum Clinical Research Darlinghurst
Darlinghurst, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Westmead Hospital - Storr Liver Centre
Westmead, New South Wales, Australia
Eastern Clinical Research Unit Box Hill
Box Hill, Victoria, Australia
St Vincent's Hospital Melbourne - Gastroenterology Department
Fitzroy, Victoria, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Fiona Stanley Hospital - Hepatology
Murdoch, Western Australia, Australia
MHAT St. Ivan Rilski Gorna Oriahovitsa EOOD
Gorna Oryahovitsa, Bulgaria
Acibadem City Clinic UMHAT Tokuda EAD, Gastroenterology
Sofia, Bulgaria
UMHAT Aleksandrovska EAD, Clinic of Endocrinology and Metabolic Diseases
Sofia, Bulgaria
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.